NCT04802174
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase 1 of the study; Patients must have had at least one prior chemotherapy
Exclusions: Patients with unstable, untreated, or symptomatic brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04802174